|
1
|
Mueller F, Fuchs B and Kaser-Hotz B:
Comparative biology of human and canine osteosarcoma. Anticancer
Res. 27:155–164. 2007.PubMed/NCBI
|
|
2
|
Ottaviani G and Jaffe N: The epidemiology
of osteosarcoma. Cancer Treat Res. 152:3–13. 2009. View Article : Google Scholar
|
|
3
|
Luetke A, Meyers PA, Lewis I and Juergens
H: Osteosarcoma treatment - where do we stand? A state of the art
review. Cancer Treat Rev. 40:523–532. 2014. View Article : Google Scholar
|
|
4
|
Arslan MA, Kutuk O and Basaga H: Protein
kinases as drug targets in cancer. Curr Cancer Drug Targets.
6:623–634. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Doble BW and Woodgett JR: GSK-3: Tricks of
the trade for a multi-tasking kinase. J Cell Sci. 116:1175–1186.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Kim L and Kimmel AR: GSK3 at the edge:
Regulation of developmental specification and cell polarization.
Curr Drug Targets. 7:1411–1419. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Jope RS and Johnson GV: The glamour and
gloom of glycogen synthase kinase-3. Trends Biochem Sci. 29:95–102.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Cohen P and Frame S: The renaissance of
GSK3. Nat Rev Mol Cell Biol. 2:769–776. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Frame S and Cohen P: GSK3 takes centre
stage more than 20 years after its discovery. Biochem J. 359:1–16.
2001. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Aberle H, Bauer A, Stappert J, Kispert A
and Kemler R: β-catenin is a target for the ubiquitin-proteasome
pathway. EMBO J. 16:3797–3804. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Kroon J, in 't Veld LS, Buijs JT, Cheung
H, van der Horst G and van der Pluijm G: Glycogen synthase
kinase-3β inhibition depletes the population of prostate cancer
stem/progenitor-like cells and attenuates metastatic growth.
Oncotarget. 5:8986–8994. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Shakoori A, Mai W, Miyashita K, Yasumoto
K, Takahashi Y, Ooi A, Kawakami K and Minamoto T: Inhibition of
GSK-3 beta activity attenuates proliferation of human colon cancer
cells in rodents. Cancer Sci. 98:1388–1393. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Ougolkov AV, Fernandez-Zapico ME, Savoy
DN, Urrutia RA and Billadeau DD: Glycogen synthase kinase-3beta
participates in nuclear factor kappaB-mediated gene transcription
and cell survival in pancreatic cancer cells. Cancer Res.
65:2076–2081. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Zhou Y, Uddin S, Zimmerman T, Kang JA,
Ulaszek J and Wickrema A: Growth control of multiple myeloma cells
through inhibition of glycogen synthase kinase-3. Leuk Lymphoma.
49:1945–1953. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Cao Q, Lu X and Feng YJ: Glycogen synthase
kinase-3beta positively regulates the proliferation of human
ovarian cancer cells. Cell Res. 16:671–677. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Mirlashari MR, Randen I and Kjeldsen-Kragh
J: Glycogen synthase kinase-3 (GSK-3) inhibition induces apoptosis
in leukemic cells through mitochondria-dependent pathway. Leuk Res.
36:499–508. 2012. View Article : Google Scholar
|
|
17
|
Shakoori A, Ougolkov A, Yu ZW, Zhang B,
Modarressi MH, Billadeau DD, Mai M, Takahashi Y and Minamoto T:
Deregulated GSK3beta activity in colorectal cancer: Its association
with tumor cell survival and proliferation. Biochem Biophys Res
Commun. 334:1365–1373. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Bilim V, Ougolkov A, Yuuki K, Naito S,
Kawazoe H, Muto A, Oya M, Billadeau D, Motoyama T and Tomita Y:
Glycogen synthase kinase-3: A new therapeutic target in renal cell
carcinoma. Br J Cancer. 101:2005–2014. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Wilson W III and Baldwin AS: Maintenance
of constitutive IkappaB kinase activity by glycogen synthase
kinase-3alpha/beta in pancreatic cancer. Cancer Res. 68:8156–8163.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Hoeflich KP, Luo J, Rubie EA, Tsao MS, Jin
O and Woodgett JR: Requirement for glycogen synthase kinase-3beta
in cell survival and NF-kappaB activation. Nature. 406:86–90. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Tang QL, Xie XB, Wang J, Chen Q, Han AJ,
Zou CY, Yin JQ, Liu DW, Liang Y, Zhao ZQ, et al: Glycogen synthase
kinase-3β, NF-κB signaling, and tumorigenesis of human
osteosarcoma. J Natl Cancer Inst. 104:749–763. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Coghlan MP, Culbert AA, Cross DA, Corcoran
SL, Yates JW, Pearce NJ, Rausch OL, Murphy GJ, Carter PS, Roxbee
Cox L, et al: Selective small molecule inhibitors of glycogen
synthase kinase-3 modulate glycogen metabolism and gene
transcription. Chem Biol. 7:793–803. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Hitora T, Yamamoto T, Akisue T, Marui T,
Nakatani T, Kawamoto T, Nagira K, Yoshiya S and Kurosaka M:
Establishment and characterization of a KIT-positive and stem cell
factor-producing cell line, KTHOS, derived from human osteosarcoma.
Pathol Int. 55:41–47. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Bacci G and Lari S: Adjuvant and
neoadjuvant chemotherapy in osteosarcoma. Chir Organi Mov.
86:253–268. 2001.
|
|
25
|
Mishra R: Glycogen synthase kinase 3 beta:
Can it be a target for oral cancer. Mol Cancer. 9:1442010.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Leis H, Segrelles C, Ruiz S, Santos M and
Paramio JM: Expression, localization, and activity of glycogen
synthase kinase 3beta during mouse skin tumorigenesis. Mol
Carcinog. 35:180–185. 2002. View
Article : Google Scholar : PubMed/NCBI
|
|
27
|
Kang T, Wei Y, Honaker Y, Yamaguchi H,
Appella E, Hung MC and Piwnica-Worms H: GSK-3 beta targets Cdc25A
for ubiquitin-mediated proteolysis, and GSK-3 beta inactivation
correlates with Cdc25A overproduction in human cancers. Cancer
Cell. 13:36–47. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Beurel E and Jope RS: The paradoxical pro-
and anti-apoptotic actions of GSK3 in the intrinsic and extrinsic
apoptosis signaling pathways. Prog Neurobiol. 79:173–189. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Ougolkov AV, Fernandez-Zapico ME, Bilim
VN, Smyrk TC, Chari ST and Billadeau DD: Aberrant nuclear
accumulation of glycogen synthase kinase-3beta in human pancreatic
cancer: Association with kinase activity and tumor
dedifferentiation. Clin Cancer Res. 12:5074–5081. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Hu Y, Gu X, Li R, Luo Q and Xu Y: Glycogen
synthase kinase-3β inhibition induces nuclear factor-κB-mediated
apoptosis in pediatric acute lymphocyte leukemia cells. J Exp Clin
Cancer Res. 29:1542010. View Article : Google Scholar
|
|
31
|
Kang MH and Reynolds CP: Bcl-2 inhibitors:
Targeting mitochondrial apoptotic pathways in cancer therapy. Clin
Cancer Res. 15:1126–1132. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Liptay S, Weber CK, Ludwig L, Wagner M,
Adler G and Schmid RM: Mitogenic and antiapoptotic role of
constitutive NF-kappaB/Rel activity in pancreatic cancer. Int J
Cancer. 105:735–746. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Aggarwal BB: Nuclear factor-kappaB: The
enemy within. Cancer Cell. 6:203–208. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Van Waes C: Nuclear factor-kappaB in
development, prevention, and therapy of cancer. Clin Cancer Res.
13:1076–1082. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Heath-Engel HM, Chang NC and Shore GC: The
endoplasmic reticulum in apoptosis and autophagy: Role of the BCL-2
protein family. Oncogene. 27:6419–6433. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Lowe SW and Lin AW: Apoptosis in cancer.
Carcinogenesis. 21:485–495. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Mahoney JA and Rosen A: Apoptosis and
autoimmunity. Curr Opin Immunol. 17:583–588. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Fiandalo MV and Kyprianou N: Caspase
control: Protagonists of cancer cell apoptosis. Exp Oncol.
34:165–175. 2012.PubMed/NCBI
|
|
39
|
Yang J, Liu X, Bhalla K, Kim CN, Ibrado
AM, Cai J, Peng TI, Jones DP and Wang X: Prevention of apoptosis by
Bcl-2: Release of cytochrome c from mitochondria blocked. Science.
275:1129–1132. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Deveraux QL, Roy N, Stennicke HR, Van
Arsdale T, Zhou Q, Srinivasula SM, Alnemri ES, Salvesen GS and Reed
JC: IAPs block apoptotic events induced by caspase-8 and cytochrome
c by direct inhibition of distinct caspases. EMBO J. 17:2215–2223.
1998. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Fernandes-Alnemri T, Litwack G and Alnemri
ES: CPP32, a novel human apoptotic protein with homology to
Caenorhabditis elegans cell death protein Ced-3 and mammalian
interleukin-1 beta-converting enzyme. J Biol Chem. 269:30761–30764.
1994.PubMed/NCBI
|
|
42
|
Oliver FJ, de la Rubia G, Rolli V,
Ruiz-Ruiz MC, de Murcia G and Murcia JM: Importance of
poly(ADP-ribose) polymerase and its cleavage in apoptosis. Lesson
from an uncleavable mutant. J Biol Chem. 273:33533–33539. 1998.
View Article : Google Scholar : PubMed/NCBI
|
